drugset
drugset / Trial / NCT02258321

Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

NCT02258321 ↗

Phase 1 Completed 12 enrolled Presidio Pharmaceuticals, Inc.
RandomizedCrossoverOpen-label

Summary

This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003.

Timeline

Start
2014-10
Primary completion
2014-10
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ravidasvir Small molecule 100 mg —
Subject Ravidasvir Small molecule 200 mg —

Indications

No indication recorded.